Merck’s New Research on Keytruda $MRK $XHS
Merck Inc., has announced new Research data on a Phase 1b study evaluating KEYTRUDA; (Pembrolizumab). The said medicine is used in advanced non-small cell lung cancer (NSCLC). View the full release here.
Merck’s New Research on Keytruda $MRK $XHS Read More »